W Cai1, Y Zhuang2, J Chen1, H Wang1. 1. Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. 2. Department of Biostatistics, School of Public Health, Southern Medical University, Guangdong Provincial Key Laboratory of Tropical Disease Research, Guangzhou 510515, China.
Abstract
OBJECTIVE: To evaluate the effect of postmastectomy radiotherapy (PMRT) on the overall survival (OS) and breast cancer-specific survival (BCSS) of patients with metaplastic breast cancer (MpBC) in comparison with those of patients with invasive ductal breast carcinoma (IDC). METHODS: We selected the patients with pathologically confirmed MpBC and IDC who either received PMRT or not from the archived cases (from January, 1998 to December, 2016) in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database. In total, 31 982 patients were selected, including 308 patients with MpBC and PMRT, 629 with MpBC and PMRT, and 31 045 with IDC and PMRT. All the included patients were above 18 years of age without distant metastases or a second primary cancer and underwent radical surgery. Baseline characteristics of the patients were compared among the 3 subgroups, and multivariate Cox regression and Kaplan-Meier analyses were performed for analyzing the prognostic factors of MpBC, OS, and BCSS. RESULTS: The majority (81.2%) of patients with MpBC were older than 50 years, had pathological grade III (68%), and were negative for ER (75.9%) and PR (79.8%) and in stage T2-3 (71.3%) and N0-1 (85.6%). Multivariate Cox regression analysis showed that age, T stage, N stage, PMRT, and chemotherapy were significantly associated with the prognosis of patients with MpBC (P < 0.05), while pathological grade, ER status, or PR status did not significantly affect the prognosis (P>0.05). Kaplan-Meier analysis showed that the patients with MpBC and PMRT had better OS (HR=1.394, 95% CI: 1.125-1.727; P < 0.05) and BCSS (HR=1.390, 95% CI: 1.074-1.800; P < 0.05) than those with MpBC who did not receive PMRT; but after PMRT, the patients with MpBC had worse OS (HR=1.626, 95%CI: 1.386-1.908; P < 0.001) and BCSS (HR=1.710, 95% CI: 1.418-2.062; P < 0.001) as compared with those with IDC. CONCLUSION: MpBC has unique clinicopathological features. In patients with MpBC, age, T stage, N stage, radiotherapy and chemotherapy are all the prognostic factors affecting the survival outcomes, and PMRT can improve the OS and BCSS of the patients.
OBJECTIVE: To evaluate the effect of postmastectomy radiotherapy (PMRT) on the overall survival (OS) and breast cancer-specific survival (BCSS) of patients with metaplastic breast cancer (MpBC) in comparison with those of patients with invasive ductal breast carcinoma (IDC). METHODS: We selected the patients with pathologically confirmed MpBC and IDC who either received PMRT or not from the archived cases (from January, 1998 to December, 2016) in the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database. In total, 31 982 patients were selected, including 308 patients with MpBC and PMRT, 629 with MpBC and PMRT, and 31 045 with IDC and PMRT. All the included patients were above 18 years of age without distant metastases or a second primary cancer and underwent radical surgery. Baseline characteristics of the patients were compared among the 3 subgroups, and multivariate Cox regression and Kaplan-Meier analyses were performed for analyzing the prognostic factors of MpBC, OS, and BCSS. RESULTS: The majority (81.2%) of patients with MpBC were older than 50 years, had pathological grade III (68%), and were negative for ER (75.9%) and PR (79.8%) and in stage T2-3 (71.3%) and N0-1 (85.6%). Multivariate Cox regression analysis showed that age, T stage, N stage, PMRT, and chemotherapy were significantly associated with the prognosis of patients with MpBC (P < 0.05), while pathological grade, ER status, or PR status did not significantly affect the prognosis (P>0.05). Kaplan-Meier analysis showed that the patients with MpBC and PMRT had better OS (HR=1.394, 95% CI: 1.125-1.727; P < 0.05) and BCSS (HR=1.390, 95% CI: 1.074-1.800; P < 0.05) than those with MpBC who did not receive PMRT; but after PMRT, the patients with MpBC had worse OS (HR=1.626, 95%CI: 1.386-1.908; P < 0.001) and BCSS (HR=1.710, 95% CI: 1.418-2.062; P < 0.001) as compared with those with IDC. CONCLUSION: MpBC has unique clinicopathological features. In patients with MpBC, age, T stage, N stage, radiotherapy and chemotherapy are all the prognostic factors affecting the survival outcomes, and PMRT can improve the OS and BCSS of the patients.
Entities:
Keywords:
breast cancer-specific survival; metaplastic breast cancer; overall survival; postmastectomy radiotherapy
Authors: Cecilia T Ong; Brittany M Campbell; Samantha M Thomas; Rachel A Greenup; Jennifer K Plichta; Laura H Rosenberger; Jeremy Force; Allison Hall; Terry Hyslop; E Shelley Hwang; Oluwadamilola M Fayanju Journal: Ann Surg Oncol Date: 2018-05-31 Impact factor: 5.344
Authors: Xuexin He; Jiali Ji; Rongrong Dong; Hong Liu; Xiaolan Dai; Chongjian Wang; Francisco J Esteva; Sai-Ching Jim Yeung Journal: Breast Cancer Res Treat Date: 2018-10-19 Impact factor: 4.872
Authors: Emarene Kalaw; Malcolm Lim; Jamie R Kutasovic; Anna Sokolova; Lucinda Taege; Kate Johnstone; James Bennett; Jodi M Saunus; Colleen Niland; Kaltin Ferguson; Irma Gresshoff; Mark Bettington; Nirmala Pathmanathan; Gary M Tse; David Papadimos; Rajadurai Pathmanathan; Gavin Harris; Rin Yamaguchi; Puay Hoon Tan; Stephen Fox; Sandra A O'Toole; Peter T Simpson; Sunil R Lakhani; Amy E McCart Reed Journal: Br J Cancer Date: 2020-09-17 Impact factor: 7.640
Authors: Lea A Moukarzel; Lorenzo Ferrando; Arnaud Da Cruz Paula; David N Brown; Felipe C Geyer; Fresia Pareja; Salvatore Piscuoglio; Anastasios D Papanastasiou; Nicola Fusco; Caterina Marchiò; Nadeem R Abu-Rustum; Rajmohan Murali; Edi Brogi; Hannah Y Wen; Larry Norton; Robert A Soslow; Anne Vincent-Salomon; Jorge S Reis-Filho; Britta Weigelt Journal: Mol Oncol Date: 2021-02-19 Impact factor: 6.603